Trial Profile
Phase 2 Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Enobosarm (Primary)
- Indications Stress incontinence
- Focus Therapeutic Use
- Sponsors GTx
- 12 Sep 2023 Status changed from discontinued to withdrawn prior to enrolment due to lack of efficacy .
- 27 Sep 2018 Status changed from recruiting to discontinued due to lack of efficacy
- 11 Jun 2018 Status changed from not yet recruiting to recruiting.